Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence

Therapeutic Drug Monitoring

Volumn 36, Issue 2, 2014, Pages 218-224

  Milman, Garry ^a   Bergamaschi, Mateus M ^a   Lee, Dayong ^a   Mendu, Damodara R ^a   Barnes, Allan J ^a   Vandrey, Ryan ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Cannabinoids; Dronabinol; Oral administration; Plasma; Smoking

Indexed keywords

11 HYDROXYDRONABINOL; CANNABINOID; DRONABINOL; PLACEBO; TETRAHYDROCANNABINOLIC ACID;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CLINICAL ARTICLE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISPOSITION; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED; PRIORITY JOURNAL; PROVOCATION TEST; QUANTITATIVE ANALYSIS; TREATMENT DURATION; WITHDRAWAL SYNDROME; YOUNG ADULT; ADOLESCENT; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MARIJUANA ABUSE; SUBSTANCE WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; CANNABINOIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84897031414     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182a5c446     Document Type: Article

References (25)

1. Drug Enforcement Administration. Federal Register 64 FR 35928. 1999. Available at: Http://www.gpo.gov/fdsys/pkg/FR-1999-07-02/pdf/99- 16833.pdf. Accessed February 18, 2013
2. US Food and Drug Administration. Drugs@FDA: FDA approved drug products. Available at: Http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.DrugDetails. Accessed February 18, 2013
3. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006;105:1-25
4. Vandrey RG, Budney AJ, Moore BA, et al. A cross-study comparison of cannabis and tobacco withdrawal. Am J Addict. 2005;14:54-63
5. Budney AJ, Vandrey RG, Hughes JR, et al. Comparison of cannabis and tobacco withdrawal: Severity and contribution to relapse. J Subst Abuse Treat. 2008;35:362-368
6. Levin KH, Copersino ML, Heishman SJ, et al. Cannabis withdrawal symptoms in non-Treatment-seeking adult cannabis smokers. Drug Alcohol Depend. 2010;111:120-127
7. Budney AJ, Vandrey RG, Hughes JR, et al. Oral delta-9- Tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend. 2007;86: 22-29
8. Levin FR, Mariani JJ, Brooks DJ, et al. Dronabinol for the treatment of cannabis dependence: A randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116:142-150
9. Vandrey R, Stitzer ML, Mintzer MZ, et al. The dose effects of short-Term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend. 2012;128:64-70
10. Karschner EL, Schwilke EW, Lowe RH, et al. Do delta9-Tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction. 2009; 104:2041-2048
11. Bergamaschi MM, Karschner EL, Goodwin RS, et al. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem. 2013;59:519-526
12. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16:276-282
13. Huestis MA, Sampson AH, Holicky BJ, et al. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992;52: 31-41
14. Lemberger L, Weiss JL, Watanabe AM, et al. Delta-9-Tetrahydrocannabinol. Temporal correlation of the psychologic effects and blood levels after various routes of administration. N Engl J Med. 1972;286:685-688
15. Huestis MA, Elsohly M, Nebro W, et al. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther Drug Monit. 2006;28:540-544
16. Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-Tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983;34:352-363
17. Sporkert F, Pragst F, Ploner CJ, et al. Pharmacokinetic investigations and delta-9-Tetrahydrocannabinol and its metabolites after single administration of 10 mg marinol in attendance of a psychiatric study. Paper presented at: Annual Meeting of The International Association of Forensic Toxicologists; August 26-30, 2001; Prague, Czech Republic; 62
18. Ohlsson A, Lindgren JE, Wahlen A, et al. Plasma delta-9- Tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28:409-416
19. Goodwin RS, Gustafson RA, Barnes A, et al. Delta(9)-Tetrahydrocannabinol, 11-hydroxy-delta(9)-Tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)- tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit. 2006;28:545-551
20. Schwilke EW, Schwope DM, Karschner EL, et al. Delta9- tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem. 2009;55:2180-2189
21. Lowe RH, Karschner EL, Schwilke EW, et al. Simultaneous quantification of delta9-Tetrahydrocannabinol, 11-hydroxy-delta9-Tetrahydrocannabinol, and 11-nor-delta9-Tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J Chromatogr A. 2007; 1163:318-327
22. Hart CL, Haney M, Ward AS, et al. Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend. 2002;67: 301-309
23. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology. 2004;29: 158-170
24. Huestis MA. Marijuana. In: Levine B, ed. Principles of Forensic Toxicology. Washington, DC: AACC Press; 2003:246-264
25. Peat MA. Distribution of delta-9-Tetrahydrocannabinol and its metabolites. In: Baselt RC, ed. Advances in Analytical Toxicology II. Chicago, IL: Year Book Medical Publishers; 1989:186-217.